the%20word%20news%20written%20with%20lea

Contact Us

Sano Chemicals Inc.

905 Innovation Drive

Bryan, Texas 77808

Email: info@sanochemicals.com

Tel: 855-384-7266 (Sano)

Fax: 866-438-4013

sano1.png

In The News

2021

 

January 29th – James Smith (CEO) and Ravi Orugunty (VP of product Development) publish manuscript:

                    Foxfire A, Buhrow AR, Orugunty RS, Smith L. Drug discovery through the isolation of natural                      products from Burkholderia. Expert Opin Drug Discov. 2021 Jan 29:1-16. doi:                                                10.1080/17460441.2021.1877655. Epub ahead of print. PMID: 33467922.

2020

December 1st – David Goodstein joins Sano Chemicals team as Chief Financial Officer

November 17th – James Smith (CEO), Frank Austin (Co-Founder) and Shien Lu (Co-Founder)                                        publish manuscript:

                  Ravichandran A, Escano J, Lee JH, Ross MK, Austin F, Orugunty R, Lu SE, Smith L.                                        Formulation, Pharmacological Evaluation, and Efficacy Studies of Occidiofungin, a Novel                            Antifungal. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01737-20. doi:                                              10.1128/AAC.01737-20. PMID: 32958713; PMCID: PMC7674058.

August 12th - Sano Chemicals receives research award from National Institute of Allergy and Infectious                       Diseases (NIAID-NIH). “A NOVEL THERAPEUTIC AGENT FOR THE TREATMENT OF GRAM-                     POSITIVE INFECTIONS” Total Funding: $233.1 K

June 2nd – Sano Chemicals selected to be MassChallenge cohort.                                                                                     (https://masschallenge.org/announcement/masschallenge-texas-in-austin-announces-2020-                       cohort)

May 26th - James Smith (CEO) and Ravi Orugunty (VP of Product Development) accepted in SWICORPS                      Summer 2020 Regional Workshops, NSF Southwest I-CorpsTM Node.

May 8th - James Smith (CEO) and Ravi Orugunty (VP of Product Development) pitch to MassChallenge                        program.

April 1st – James Smith (CEO), Ravi Orugunty (VP of Product Development), and Josh Jeanson (CBO)                           attend NIH-Commercialization Accelerator Program FeedForward™ Session Washington, DC.

January 6th – George Atiee joins Sano Chemicals team as Chief Medical Officer

 

2019

November 13th – Ravi Orugunty and Josh Jeanson attend NIH-Commercialization Accelerator Program                           Commercialization Training Workshop (CTW) in Los Angeles, CA.

October 29th – James Smith (CEO) participates in an SBIR/STTR panel hosted by the School of                                         Innovation, Memorial Student Center, College Station (October 29, 2019)

September 27th – Sano Chemicals selected for the 2019-20 NIH-Commercialization Accelerator Program.

June 1st – Ravi Orugunty joins Sano Chemicals team as Vice President of Product Development

April 30th - James Smith (CEO) presents at the Department of Veterinary Physiology and Pharmacology                         (VTPP) in the College of Veterinary Medicine and Biomedical Sciences, College Station.                               Title: Occidiofungin & Other Natural Products as Novel Pharmacologic.

May 15th – James Smith (CEO) presents at Texas New Venture Challenge Keynote & Panel –                                           Commercialization at Texas A&M, Kyle Field, College Station

January 1st – James Smith (CEO) and Shien Lu (Co-Founder) publish manuscript:

                     Ravichandran A, Geng M, Hull KG, Li J, Romo D, Lu SE, Albee A, Nutter C, Gordon DM,                             Ghannoum MA, Lockless SW, Smith L. A Novel Actin Binding Drug with In Vivo Efficacy.                               Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01585-18. doi: 10.1128/AAC.01585-18.                           PMID: 30323040; PMCID: PMC6325233.

January 1st – James Smith (CEO) publishes manuscript:

                    Geng M, Deng P, Mire T, Austin F, Smith L. Draft Genome Sequence of the Lantibiotic-                                Producing Strain Streptococcus salivarius HS0302. Microbiol Resour Announc. 2019 Jan                              3;8(1):e01410-18. doi: 10.1128/MRA.01410-18. PMID: 30637392; PMCID: PMC6318363.

 

2018

November 26th – James Smith (CEO) publishes manuscript:

                    Geng M, Ravichandran A, Escano J, Smith L. Efficacious Analogs of the Lantibiotic Mutacin                        1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection. Antimicrob                           Agents Chemother. 2018 Nov 26;62(12):e01626-18. doi: 10.1128/AAC.01626-18. PMID:                                 30275083; PMCID: PMC6256755.

August 1st – James Smith (CEO) publishes manuscript:

                    Geng M, Smith L. Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and                          Stability. Appl Environ Microbiol. 2018 Jul 17;84(15):e00830-18. doi: 10.1128/AEM.00830-18.                        PMID: 29776930; PMCID: PMC6052277.

July 25th – Sano Chemicals enter license agreement with Indigo Ag for development of antifungal                                 technology for agricultural products.

March 15th - Sano Chemicals receives research award from National Institute of Allergy and Infectious                          Diseases (NIAID-NIH). “PRECLINICAL DEVELOPMENT OF OCF001 FOR TREATMENT OF                          YEAST INFECTIONS” Total Funding: $2.9 M

March 1st – James Smith (CEO) publishes manuscript:

                     Geng M, Austin F, Shin R, Smith L. Covalent Structure and Bioactivity of the Type AII                                     Lantibiotic Salivaricin A2. Appl Environ Microbiol. 2018 Feb 14;84(5):e02528-17. doi:                                     10.1128/AEM.02528-17. PMID: 29269497; PMCID: PMC5812933.

February 13th – James Smith (CEO) publishes manuscript:

                     Geng M, Smith L. Improving the attrition rate of Lanthipeptide discovery for commercial                             applications. Expert Opin Drug Discov. 2018 Feb;13(2):155-167. doi:                                                                 10.1080/17460441.2018.1410137. Epub 2017 Dec 1. PMID: 29195488.

January 15th – John Ferreira joins Sano Chemicals team as Vice President of Quality Operations

 

2017

July 15th – James Smith (CEO) publishes manuscript:

                     Escano J, Ravichandran A, Salamat B, Smith L. Carboxyl Analogue of Mutacin 1140, a                                   Scaffold for Lead Antibacterial Discovery. Appl Environ Microbiol. 2017 Jun                                                   30;83(14):e00668-17. doi: 10.1128/AEM.00668-17. PMID: 28500042; PMCID: PMC5494638.

April 15th – James Smith (CEO) and Shien Lu (Co-Founder) publish manuscript:

                     Deng P, Foxfire A, Xu J, Baird SM, Jia J, Delgado KH, Shin R, Smith L, Lu SE. The                                           Siderophore Product Ornibactin Is Required for the Bactericidal Activity of Burkholderia                               contaminans MS14. Appl Environ Microbiol. 2017 Mar 31;83(8):e00051-17. doi:                                               10.1128/AEM.00051-17. PMID: 28188204; PMCID: PMC5377494.

February 14th - Sano Chemicals receives research award from National Institute of Allergy and Infectious                       Diseases (NIAID-NIH). “LEAD COMPOUND DISCOVERY FROM ENGINEERED ANALOGS                         OF OCCIDIOFUNGIN” Total Funding: $224.9k

 

2016

June 2nd – James Smith (CEO) and Shien Lu (Co-Founder) publish manuscript:

                    Escano J, Deng P, Lu SE, Smith L. Draft Genome Sequence of Oral Bacterium Streptococcus                      mutans JH1140. Genome Announc. 2016 Jun 2;4(3):e00472-16.  doi:                                                                10.1128/genomeA.00472-16. PMID: 27257196; PMCID: PMC4891642.

March 14th – Sano Chemicals receives research award from National Institute of Allergy and Infectious                          Diseases (NIAID-NIH). “OPTIMIZATION OF THE PRODUCTION AND ISOLATION OF THE                          NOVEL ANTIFUNGAL OCCIDIOFUNGIN” Total Funding: $529.6k

January 14th – James Smith (CEO) and Shien Lu (Co-Founder) publish manuscript:

                    Deng P, Wang X, Baird SM, Showmaker KC, Smith L, Peterson DG, Lu S. Comparative                                  genome-wide analysis reveals that Burkholderia contaminans MS14 possesses multiple                                antimicrobial biosynthesis genes but not major genetic loci required for pathogenesis.                                Microbiologyopen. 2016 Jun;5(3):353-69. doi: 10.1002/mbo3.333. Epub 2016 Jan 14. PMID: 2                      26769582; PMCID: PMC4905989.

 

2015

December 21st – James Smith (CEO) and Shien Lu (Co-Founder) publish manuscript:

                    Wang XQ, Liu AX, Guerrero A, Liu J, Yu XQ, Deng P, Ma L, Baird SM, Smith L, Li XD, Lu SE.                          Occidiofungin is an important component responsible for the antifungal activity of                                        Burkholderia pyrrocinia strain Lyc2. J Appl Microbiol. 2016 Mar;120(3):607-18. doi:                                        10.1111/jam.13036. PMID: 26910858.

June 3rd – Sano receives prize money from Texas New Venture Competition. Total Funding: $10 k

May 23rd – James Smith (CEO) publishes manuscript:

                   Escano J, Smith L. Multipronged approach for engineering novel peptide analogues of                               existing lantibiotics. Expert Opin Drug Discov. 2015;10(8):857-70. doi:                                                             10.1517/17460441.2015.1049527. Epub 2015 May 23. PMID: 26004576.

April 15th - Sano Chemicals Inc establishes its first research laboratory in Bryan Texas

January 20th – James Smith (CEO) publishes manuscript:

                   Escano J, Stauffer B, Brennan J, Bullock M, Smith L. Biosynthesis and transport of the                                   lantibiotic mutacin 1140 produced by Streptococcus mutans. J Bacteriol. 2015                                               Apr;197(7):1173-84. doi: 10.1128/JB.02531-14. Epub 2015 Jan 20. PMID: 25605307; PMCID:                         PMC4352662.

 

2014

November 21st – James Smith (CEO) was an invited speaker at Texas Branch American Society for                               Microbiology in Houston. Presentation: Probing for the target and mechanism of action of                           the novel antifungal occidiofungin.

November 17th – James Smith (CEO) publishes manuscript:

                   Escano J, Stauffer B, Brennan J, Bullock M, Smith L. The leader peptide of mutacin 1140 has                       distinct structural components compared to related class I lantibiotics. Microbiologyopen.                           2014 Dec;3(6):961-72. doi: 10.1002/mbo3.222. Epub 2014 Nov 17. PMID: 25400246; PMCID:                         PMC4263518.

October 23rd - James Smith (CEO) and Frank Austin (Co-Founder) publish manuscript:   

                    Lai Hing S, Ravichandran A, Escano J, Cooley J, Austin F, Smith L. Toxicological Evaluation of                      Occidiofungin against Mice and Human Cancer Cell Lines. Pharmacology & Pharmacy, 5,                            1085-1093. (2014). 2014 October; 5:1085-1093.

 

2013

May 14th – James Smith (CEO) and Shien Lu (Co-Founder) publish manuscript:

                    Emrick D, Ravichandran A, Gosai J, Lu S, Gordon DM, Smith L. The antifungal occidiofungin                        triggers an apoptotic mechanism of cell death in yeast. J Nat Prod. 2013 May 24;76(5):829-                          38. doi: 10.1021/np300678e. Epub 2013 May 14. PMID: 23672235.

May 15th – James Smith (CEO) and Shien Lu (Co-Founder)publish manuscript:

                   Chen KC, Ravichandran A, Guerrero A, Deng P, Baird SM, Smith L, Lu SE. The Burkholderia                         contaminans MS14 ocfC gene encodes a xylosyltransferase for production of the antifungal                       occidiofungin. Appl Environ Microbiol. 2013 May;79(9):2899-905. doi: 10.1128/AEM.00263-13.                      Epub 2013 Feb 22. PMID: 23435879; PMCID: PMC3623131.

April 15th – James Smith (CEO) publishes manuscript:

                   Chen S, Wilson-Stanford S, Cromwell W, Hillman JD, Guerrero A, Allen CA, Sorg JA, Smith L.                     Site-directed mutations in the lanthipeptide mutacin 1140. Appl Environ Microbiol. 2013                              Jul;79(13):4015-23. doi: 10.1128/AEM.00704-13. Epub 2013 Apr 19. PMID: 23603688; PMCID:                        PMC3697549.

March 15th – Josh Jeanson joins Sano Chemicals as the Chief Business Officer

February 21st – James Smith (CEO) was an invited speaker at Texas Life Science Venture Forum at Rice                       University.

February 15th –  James Smith (CEO) and Shien Lu (Co-Founder) publish manuscript:

                   Ravichandran A, Gu G, Escano J, Lu SE, Smith L. The presence of two cyclase thioesterases                         expands the conformational freedom of the cyclic Peptide occidiofungin. J Nat Prod. 2013                         Feb 22;76(2):150-6. doi: 10.1021/np3005503. Epub 2013 Feb 8. PMID: 23394257; PMCID:                               PMC4142711.

                   Ravichandran A, Gu G, Escano J, Lu S, and Smith L. Served with a twist, Nature Chemical                             Biology 9:215 (2013) Research Highlight-Biosynthesis.

 

2012

July 15th – James Smith (CEO), Frank Austin (Co-Founder), and Steve Pruett (Member)                                                     publish manuscript:

                    Tan W, Cooley J, Austin F, Lu SE, Pruett SB, Smith L. Nonclinical toxicological evaluation of                           occidiofungin, a unique glycolipopeptide antifungal. Int J Toxicol. 2012 Jul-Aug;31(4):326-                           36. doi: 10.1177/1091581812445185. Epub 2012 Jun 11. PMID: 22689636.

March 29th - Bridging the Gap: Early Translational Research Awards, Cancer Research Institute of Texas                        awards Dr. Smith and Texas A&M University $777,000 to promote the commercialization of a                      novel antifungal agent. (https://www.cprit.texas.gov/grants-funded/grants/rp121002)

March 15th – James Smith (CEO), Frank Austin (Co-Founder), and Shien Lu (Co-Founder)                                                publish manuscript:

                    Ellis D, Gosai J, Emrick C, Heintz R, Romans L, Gordon D, Lu SE, Austin F, Smith L.                                        Occidiofungin's chemical stability and in vitro potency against Candida species. Antimicrob                        Agents Chemother. 2012 Feb;56(2):765-9. doi: 10.1128/AAC.05231-11. Epub 2011 Nov 21.                            PMID: 22106210; PMCID: PMC3264235.

April 13th – James Smith (CEO) was an invited speaker, TAMHC Cancer Research Colloquium, Drug                              Discovery Breakout session.

March 29th – James Smith was an invited speaker at College of Science, Dean's Student Advisory Panel                        on March 29, 2012.

March 1st – Sano Chemicals is founded in College Station Texas

© 2021 by Sano Chemicals Inc.

  • Black Twitter Icon